Current State of Compassionate Phage Therapy.

Détails

Ressource 1Télécharger: viruses-11-00343-v2.pdf (634.19 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_30AAF2E954D2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current State of Compassionate Phage Therapy.
Périodique
Viruses
Auteur⸱e⸱s
McCallin S., Sacher J.C., Zheng J., Chan B.K.
ISSN
1999-4915 (Electronic)
ISSN-L
1999-4915
Statut éditorial
Publié
Date de publication
12/04/2019
Peer-reviewed
Oui
Volume
11
Numéro
4
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: epublish
Résumé
There is a current unmet medical need for the treatment of antibiotic-resistant infections, and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as phage therapy, for compassionate treatment. Phage therapy is ideal for compassionate use due to its long-standing historical use and publications, apparent lack of adverse effects, and solid support by fundamental research. Increased media coverage and peer-reviewed articles have given rise to a more widespread familiarity with its therapeutic potential. However, compassionate phage therapy (cPT) remains limited to a small number of experimental treatment centers or associated with individual physicians and researchers. It is possible, with the creation of guidelines and a greater central coordination, that cPT could reach more of those in need, starting by increasing the availability of phages. Subsequent steps, particularly production and purification, are difficult to scale, and treatment paradigms stand highly variable between cases, or are frequently not reported. This article serves both to synopsize cPT publications to date and to discuss currently available phage sources for cPT. As the antibiotic resistance crisis continues to grow and the future of phage therapy clinical trials remains undetermined, cPT represents a possibility for bridging the gap between current treatment failures and future approved alternatives. Streamlining the process of cPT will help to ensure high quality, therapeutically-beneficial, and safe treatment.
Mots-clé
Bacterial Infections/therapy, Compassionate Use Trials, Drug Resistance, Multiple, Bacterial, Humans, Phage Therapy, antibiotic resistance, bacteriophage therapy, compassionate use
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/05/2019 16:12
Dernière modification de la notice
21/11/2022 8:27
Données d'usage